NT
Intellia Therapeutics, Inc.
NTLA · NASDAQ
$12.14 -0.12% (-$0.01)
1M -1.45%
Market Cap $1.71B
P/E Ratio -
Div. Yield -
ROE 57.79%
Piotroski F-Score Weak
3/9Valuation
40 /100
Fair P/S 28.79x
P/B 2.35x
P/E N/A
Growth
49 /100
Stable Rev. growth 9.09%
Book val. growth 18.40%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 46.48%
Net margin 672.16%
FCF margin 783.30%
Quality
1 /100
Poor ROIC 52.86%
ROE 57.79%
Asset turnover 0.07x
Debt
100 /100
Low Debt/Equity 0.10x
Current ratio 6.65x
Int. coverage N/A
Stability
33 /100
Unstable Beta 1.82x
Rev. volatility 45.00%
Profitable years 0
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o NTLA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
John Leonard
Employees
377
Headquarters
Cambridge
Nadchodzące wydarzenia
05 LIS
Earnings
Upcoming earnings report